| Title: | Genome-Wide Association Study of Cardiovascular Resilience Identifies Protective Variation in the CETP Gene |
| Journal: | Journal of the American Heart Association |
| Published: | 6 Nov 2023 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/37929782/ |
| DOI: | https://doi.org/10.1161/jaha.123.031459 |
| URL: | https://www.ahajournals.org/doi/pdf/10.1161/JAHA.123.031459 |
Publication 8374
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Background The risk of atherosclerotic cardiovascular disease (ASCVD) increases sharply with age. Some older individuals, however, remain unaffected despite high predicted risk. These individuals may carry cardioprotective genetic variants that contribute to resilience. Our aim was to assess whether asymptomatic older individuals without prevalent ASCVD carry cardioprotective genetic variants that contribute to ASCVD resilience. Methods and Results We performed a genome-wide association study using a 10-year predicted ASCVD risk score as a quantitative trait, calculated only in asymptomatic older individuals aged ≥70 years without prevalent ASCVD. Our discovery genome-wide association study of N=12 031 ASCVD event-free individuals from the ASPREE (Aspirin in Reducing Events in the Elderly) trial identified 2 independent variants, rs9939224 (P<5×10-8) and rs56156922 (P<10-6), in the CETP (cholesteryl ester transfer protein) gene. The CETP gene is a regulator of plasma high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and lipoprotein(a) levels, and it is a therapeutic drug target. The associations were replicated in the UK Biobank (subpopulation of N=13 888 individuals aged ≥69 years without prevalent ASCVD). Carriers of the identified CETP variants (versus noncarriers) had higher plasma high-density lipoprotein cholesterol levels, lower plasma low-density lipoprotein cholesterol levels, and reduced risk of incident ASCVD events during follow-up. Expression quantitative trait loci analysis predicted the identified CETP variants reduce CETP gene expression across various tissues. Previously reported associations between genetic CETP inhibition and increased risk of age-related macular degeneration were not observed among the 3917 ASPREE trial participants with retinal imaging and genetic data available. Conclusions Common genetic variants in the CETP gene region are associated with cardiovascular resilience during aging. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT01038583.</p>
17 Authors
- Chenglong Yu
- Andrew Bakshi
- Gerald F. Watts
- Alan E. Renton
- Brian Fulton-Howard
- Alison M. Goate
- Pradeep Natarajan
- Daniel I. Chasman
- Liubov Robman
- Robyn L. Woods
- Robyn Guymer
- Rory Wolfe
- Le Thi Phuong Thao
- John J. McNeil
- Andrew M. Tonkin
- Stephen J. Nicholls
- Paul Lacaze
1 Application
| Application ID | Title |
|---|---|
| 47061 | Comparing polygenic risk and predicted loss-of-function (pLoF) variants in a healthy ageing cohort (ASPREE) with the UK Biobank, across a range of disease and health-related phenotypes |
Enabling scientific discoveries that improve human health